The Accretion Nutraveda IPO is one of the notable upcoming SME public offerings in the Indian markets in early 2026. Aimed at raising capital for expansion and operational needs, this IPO presents an opportunity for investors looking to participate in the growing Ayurvedic and nutraceutical manufacturing segment. In this comprehensive guide, we cover all the essential Accretion Nutraveda IPO Details, including dates, price band, lot size, subscription process, and Accretion Nutraveda IPO GMP outlook.
What Is the Accretion Nutraveda IPO?
The Accretion Nutraveda IPO is a book-built public issue by Accretion Nutraveda Ltd., a company engaged in the manufacturing of Ayurvedic and nutraceutical products. Founded in 2021, the company produces a range of healthcare formulations including tablets, capsules, liquids, and powders under strict quality standards. Its products cater to both domestic and international markets, supported by certifications like WHO-GMP, FSSAI, ISO and Halal, positioning it well within a high-growth wellness sector.
This IPO is structured as an SME (Small and Medium Enterprises) offer and will be listed on the BSE SME exchange upon completion.
Accretion Nutraveda IPO 2026 – Key Dates
Investors looking to apply for the Accretion Nutraveda IPO 2026 need to mark several important dates:
- IPO Opening Date: 27 January 2026
- IPO Closing Date: 30 January 2026
- Allotment Date: 2 February 2026
- Refunds Initiation: 3 February 2026
- Listing Date: 4 February 2026 (on BSE SME)
These dates form the primary timeline for subscription and listing, offering investors a window to apply and track their investments.
Accretion Nutraveda IPO Price and Lot Size
The Accretion Nutraveda IPO Price band has been fixed between ₹122 and ₹129 per equity share, with a face value of ₹10 each.
For applications:
- Lot Size: 1,000 shares
- Minimum Investment: ₹2,58,000 (2 lots)
- Retail Allocation: Minimum 2,000 shares per investor
These pricing and lot specifications set the entry point for retail and other categories of investors.
Here’s a clean rewrite of that section, replacing Issue Size & Allocation with a Key Performance Indicators / Competitive Strength focus, while keeping a professional IndiaIPO-style tone:
Accretion Nutraveda IPO Details – Key Performance Indicators
Accretion Nutraveda Ltd. operates in a fast-growing Ayurvedic and nutraceutical segment, supported by several strong performance indicators that enhance its business stability and long-term growth potential. The company’s operational strengths reflect its ability to compete effectively in a regulated and quality-driven market.
Competitive Strengths
- Diversified Product Portfolio:
The company offers a wide range of Ayurvedic and nutraceutical formulations, including tablets, capsules, powders, and liquid products. This diversified portfolio helps reduce dependency on a single product line while catering to varied customer requirements. - High Quality & Compliance Standards:
Accretion Nutraveda follows strict quality control processes and operates in compliance with recognized certifications, ensuring consistency, safety, and reliability across its product offerings. - Strong Customer & Supplier Relationships:
Long-standing relationships with customers and trusted suppliers support uninterrupted production, efficient sourcing of raw materials, and repeat business opportunities. - Experienced Promoters & Management Team:
The company is led by promoters and a management team with significant industry experience and domain expertise. Their operational knowledge and strategic oversight play a key role in business expansion and execution efficiency.
These key performance indicators position Accretion Nutraveda as a competitive player in the wellness and nutraceutical manufacturing space, supporting its growth strategy post listing.
Why Is Accretion Nutraveda Issuing This IPO?
A primary reason behind launching the Accretion Nutraveda IPO is to fund strategic business objectives aimed at improving the company’s production and competitive edge:
- Purchasing New Machinery: Automating existing operations and acquiring equipment for new manufacturing lines.
- Working Capital Requirements: Enhancing day-to-day operational funding.
- Facility Expansion: Increasing manufacturing capacity to serve broader markets.
An IPO proceeds usage breakdown like this signals the company’s focus on sustainable, growth-oriented capital deployment.
Accretion Nutraveda IPO GMP – Grey Market Insights
One of the key terms investors often watch is the Accretion Nutraveda IPO GMP (Grey Market Premium), which reflects the unofficial price premium investors might be willing to pay prior to listing. As per available data before the IPO subscribed, the GMP was reported at ₹0, indicating neutral sentiment and suggesting that shares might list around the upper price band without significant early premium gains.
It’s important to note that GMP is an informal indicator and subject to swift changes based on subscription trends and market conditions.
Is This IPO a Good Bet?
The Accretion Nutraveda IPO offers exposure to a niche yet expanding segment of healthcare products. With certified manufacturing processes and a diversified product range, the company is well-placed in a sector backed by strong consumer demand for wellness and traditional medicine.
However, prospective investors should weigh typical SME IPO risks such as limited liquidity post-listing and dependence on production performance against growth prospects before applying.
Conclusion
The Accretion Nutraveda IPO 2026 stands out as a noteworthy SME offering with clear operational use of funds, structured allocation across investor classes, and defined Accretion Nutraveda IPO Details. Whether you are a seasoned investor or new to public offers, understanding the IPO timeline, pricing, and market expectations — including Accretion Nutraveda IPO Price and Accretion Nutraveda IPO GMP — will help in making an informed investment choice.
If you’re considering applying, stay updated with official filings and subscription trends as the IPO window progresses. Click here for as similar information.
